ENROUTE Transcarotid Stent System
BOSTON SCIENTIFIC CORPORATION · Decision date Jan 8, 2026
What did the FDA decide?
FDA records P140026/S033 as a supplement to PMA P140026, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Jan 8, 2026.
FDA approval order statement
approval to change the receiving inspection level for 15 part numbers
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Jan 8, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P140026/S033
- Regulatory pathway
- PMA supplement
- Applicant
- BOSTON SCIENTIFIC CORPORATION
- Product code
- NIM
- Decision code
- OK30
- Decision date
- Jan 8, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Stent, carotid.
- Applicant
- Boston Scientific Corporation
- Product code
- NIM
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P140026/S032 · Related supplement
ENROUTE Transcarotid Stent System
P140026/S033 received
Application receipt date recorded by FDA.
P140026/S033 · FDA decision
30-Day Notice
Timeline entries are records held by MedtechLedger for P140026. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P140026
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
ENROUTE Transcarotid Stent SystemP140026/S032 | BOSTON SCIENTIFIC CORPORATION | PMA supplement | Oct 23, 2025 | FDA |
Explore the linked device profile
Other records with product code NIM
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
PROTEGE GPS AND PROTEGE RX CAROTID STENT SYSTEMSP060001/S060 | Medtronic Vascular, Inc. | PMA supplement | Nov 5, 2026 | FDA |
| Contego Medical, Inc. | PMA supplement | Nov 4, 2026 | FDA | |
| Medtronic Vascular, Inc. | PMA supplement | Oct 16, 2026 | FDA | |
| Contego Medical, Inc. | PMA supplement | Jul 29, 2026 | FDA | |
| Medtronic Vascular, Inc. | PMA supplement | Jul 10, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Boston Scientific Corporation
- Headquarters
- Not reported
- Brand website
- bostonscientific.com
- FDA applicant address
- 300 Boston Scientific Way, Marborough, MA, 01752
Sources and methodology
- Original FDA record: P140026/S033
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



